As the global landscape of biotechnology evolves, Europe finds itself in a fierce competition with the United States, China, and emerging life sciences hubs. The upcoming Advanced Therapies Europe 2026 conference aims to address a critical question: How can Europe sustain its competitiveness in the field of cell and gene therapy (CGT)?
A Gathering of Innovators
Scheduled to take place in Barcelona from September 7 to 9, 2026, this sixth edition of Advanced Therapies Europe will bring together industry leaders, investors, regulators, and therapy developers. The event’s primary focus will be on actionable strategies that can bolster Europe’s standing in advanced therapies. Concerns about regulatory complexities, fragmented healthcare systems, and investment hurdles have hindered Europe’s ability to transform scientific advancements into commercial successes at a rate comparable to its global counterparts.
Keynote Insights
The conference will kick off with a keynote address from Professor Jacob George, the newly appointed Chief Medical and Scientific Officer for the MHRA. He is set to share valuable insights into the evolving regulatory framework and its potential impact on enhancing Europe’s competitiveness in advanced therapies. Following the keynote, a panel of industry leaders will engage in discussions centered on how Europe can expedite approvals, attract investment, retain innovation, and create an environment conducive to the development, manufacturing, and launch of new therapies.
Addressing the Challenge
Kimberley Barnes, President of Phacilitate, emphasizes that Europe has already established itself as a hub for world-class scientific research. The current challenge lies in ensuring that breakthrough therapies are developed, funded, manufactured, and delivered within Europe. With increasing competition from the US, China, and other emerging biotech regions, the focus is shifting toward creating an ecosystem that allows CGT innovation to thrive on the continent.
“Advanced Therapies Europe brings together the senior decision-makers who can help make that happen,” Barnes stated. The event will feature 90 speakers, dedicated debates, and curated one-on-one discussion opportunities. The conversations in Barcelona will not only explore scientific possibilities but also spotlight the practical changes necessary to fortify Europe’s position as a global leader in advanced therapies.
Regulatory Landscape and Collaboration
Professor George notes that Europe, including the UK, possesses the scientific acumen, clinical expertise, and robust research foundation required to lead in advanced therapies. The current opportunity lies in harmonizing regulation, innovation, and collaboration to ensure that promising therapies reach patients efficiently while upholding the highest safety and quality standards.
Advanced Therapies Europe serves as a vital platform for stakeholders to convene and strategize on how to facilitate progress and ensure that patients benefit from contemporary innovations.
New Features for 2026
The 2026 conference will introduce new debate sessions focused on some of the sector’s most pressing and controversial topics. This includes the return of the Investment Summit, alongside ATE Connect, which consists of closed-door discussions aimed at fostering strategic partnerships and candid dialogues among senior leaders.
Building Connections
Hosted at the InterContinental Barcelona, Advanced Therapies Europe will welcome a diverse array of attendees, from therapeutic developers and investors to regulators, healthcare leaders, and technology providers. The event will limit participation to 600 delegates to foster deeper engagement and meaningful connections among participants.
Conclusion
Advanced Therapies Europe 2026 promises to be a pivotal event in shaping the future of cell and gene therapy in Europe. By addressing regulatory challenges and fostering collaboration, the conference aims to create an environment where innovation can flourish. As stakeholders come together to share insights and strategies, the potential for groundbreaking therapies to emerge from Europe has never been more promising.
- Key discussions on regulatory frameworks and investment strategies will be central.
- Networking opportunities will facilitate connections among industry leaders.
- The event will highlight Europe’s scientific capabilities and innovation potential.
- New debate sessions will tackle critical issues facing the CGT sector.
- Collaboration is emphasized as a pathway to accelerate therapy development and delivery.
Read more → pmlive.com